Esreboxetine
- Generic Name
- Esreboxetine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H23NO3
- CAS Number
- 98819-76-2
- Unique Ingredient Identifier
- L8S50ZY490
- Background
Esreboxetine has been used in trials studying the treatment and basic science of Fibromyalgia.
- Associated Conditions
- -
- Associated Therapies
- -
Phase 1 Thorough QT (TQT) Study in Young Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2011-04-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT00809289
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Maintenance of Efficacy.
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00796601
A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia.
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 89
- Registration Number
- NCT00752505
- Locations
- 🇺🇸
Pfizer Investigational Site, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath